Molecular Analysis of Patients With Neuromuscular Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-100
SponsorBoston Children's Hospital

About this trial

The purpose of this study is to identify new genes responsible for neuromuscular disorders and study muscle tissue of patient with known neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy with no causative gene implicated in their disease. Using molecular genetics to unravel basis of these neuromuscular disorders will lead to more accurate diagnosis/prognosis of these disorders which will lead to potential therapies.

Eligibility criteria

Qualifiers

having a clinical and/or pathological diagnosis of a muscular dystrophy

being the first degree relative of someone with such a diagnosis

having had a muscle biopsy if diagnosed with a neuromuscular disease

willingness to provide a skin biopsy for research only

Disqualifiers

not having a neuromuscular diagnosis in you or a family member

not wishing to participate

being incapable of giving consent and not having a legal guardian willing or able to do so

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Boston Children's Hospital

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator